Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma

ConclusionsOur study suggests that patients with lung adenocarcinoma bearing a EGFR-mutation have a decreased risk of VTE compared with patients with other forms of lung adenocarcinoma. Targeted therapy with TKI alone or in combination with other treatments seems to reduce the risk of VTE compared to other treatments not including TKI.
Source: Multidisciplinary Respiratory Medicine - Category: Respiratory Medicine Source Type: research